# Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation

Study · id `cardio:ct-nct01002339` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01002339](<https://clinicaltrials.gov/study/NCT01002339>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01002339

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 134 participants.

## Technical summary

Registry record NCT01002339. Randomized; no masking; primary purpose prevention. Start 2010-02 (registry gives no type); primary completion 2014-02 (actual). Results posted on 2016-08-03.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 134 participants (enrolled count; ClinicalTrials.gov record NCT01002339, source copy `cardio:ctgov-nct01002339-2024-10-22`, retrieved 2026-10-26)
- Start date: 2010-02 (registry gives no type) (ClinicalTrials.gov record NCT01002339, source copy `cardio:ctgov-nct01002339-2024-10-22`, retrieved 2026-10-26)
- Primary completion: 2014-02 (actual) (ClinicalTrials.gov record NCT01002339, source copy `cardio:ctgov-nct01002339-2024-10-22`, retrieved 2026-10-26)
- Completion: 2015-06 (actual) (ClinicalTrials.gov record NCT01002339, source copy `cardio:ctgov-nct01002339-2024-10-22`, retrieved 2026-10-26)
- Results first posted: 2016-08-03 (ClinicalTrials.gov record NCT01002339, source copy `cardio:ctgov-nct01002339-2024-10-22`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT01002339, source copy `cardio:ctgov-nct01002339-2024-10-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01002339-2024-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation
- Acronym: 01-DMPT
- Condition: Diabetes Mellitus, Adult-Onset
- Intervention (Drug): Tacrolimus with rapid steroid withdrawal
- Intervention (Drug): Tacrolimus with steroids minimization
- Intervention (Drug): CsA with steroid minimization
- Lead sponsor: Armando Torres Ramírez
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 5139524d20084412dee4417d50bc4b95f0ac3f0a4b628ae3b56652c41ecbbd88
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
